CohBar, Inc. Announces Discovery of New Peptides in the Mitochondrial Genome
Company Expands IP Portfolio with 25 New Provisional Patent Applications
MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat diseases associated with aging, today announced the discovery of a large number of new biologically active peptides encoded within the genome of the mitochondria, together with the filing of 25 new provisional patent applications. The company is evaluating these peptides as possible additions to its pipeline of MBTs, and expects to file additional patent applications going forward.
"Breakthrough research by our founding scientists revealed the potential for dozens of mitochondrial-derived peptides, and we’re taking the next major step forward by using our proprietary technology platform to identify specific peptides with the greatest therapeutic potential," said Ken Cundy, CohBar’s CSO. “If the broad range of metabolic and disease-related effects demonstrated by our current pipeline candidates in preclinical models is any indication, these new peptides could have significant potential for addressing a wide range of age-related diseases.”
“From our early research we were confident that there were dozens of new peptides in the mitochondrial genome, and our continuing research suggests there are many more,” said Dr. Pinchas Cohen, Dean of the USC Leonard Davis School of Gerontology, and a CohBar founder and director. “Growing activity and evidence in the research community continue to highlight the significant evolution-crafted roles that mitochondrial-derived peptides play in metabolism, health and disease, which are particularly relevant to our aging population, whose quality of life and longevity are most impacted by metabolic dysfunction. I expect to see many more discoveries with significant therapeutic potential in the future.”
“We believe that these new discoveries, together with our existing pipeline, will help secure our position going forward as the leader in mitochondria based therapeutics,” said Simon Allen, CohBar CEO. “I’m particularly pleased that our team has been able to make these significant discoveries while simultaneously advancing our recently announced CB4209 and CB4211 candidates into IND-enabling activities. Going forward, we will continue to move our lead program toward the clinic, while prioritizing the most promising of these new discoveries for near-term internal development and partnership opportunities.”
As a reminder, CohBar will host a conference call and WebEx for investors today, October 13, 2016, to provide additional details on the Company’s preclinical studies and the potential of these MBTs to address the unmet medical needs and market opportunities in obesity, NASH and type 2 diabetes.
Conference Call and WebEx Information:
Date: October 13, 2016
Time: 1:30 p.m. (PST)
Audio, Dial-in U.S. and Canada: (888) 634-7543
Audio, Dial-in International: (719) 325-2370
Conference ID#: 6208160
To join the WebEx please go to: https://signin.webex.com/collabs/#/meetings/joinbynumber
Enter Meeting Number: 191952565
Also available here: https://meetings.webex.com/collabs/#/meetings/detail?uuid=M86HOM1FAIU0T5AFT676KJ5HHB-7UA1&rnd=516521.25772
The Mitochondrial Genome and CohBar’s MBTs
Mitochondria, the only parts of the cell other than the nucleus that have their own genome, produce energy and regulate cell death in response to signals received from the cell. Until recently, scientists believed the mitochondrial genome contained only 37 genes and, as a result, it had been relatively unexplored as a focus of drug discovery efforts. Research by CohBar founders and their academic collaborators revealed that the mitochondrial genome has dozens of potential new genes that encode peptides. In preclinical models of age-related diseases, a number of these peptides have shown potential disease-modifying effects including metabolic, neuro-protective, cyto-protective and anti-inflammatory effects. CohBar’s efforts are focused on applying our platform technology to explore the mitochondrial genome for new peptides that exhibit biological activity, and optimize them using industry accepted disease models to create proprietary MBTs for a wide range of age-related diseases.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a leader in the research and development of mitochondria-based therapeutics, an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as type 2 diabetes, obesity, NASH, cancer, atherosclerosis and neurodegenerative disorders.
For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements, including: statements concerning CohBar’s plans, prospects, resources and capabilities, including statements regarding its research and development activities, expectations regarding the therapeutic potential of mitochondrial-derived peptides, potential for additional discoveries, and expectations regarding future patent applications. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include the possibility of unfavorable research results and CohBar’s ability to obtain capital, retain key personnel, expand its research operations, and successfully advance its drug discovery and development programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Anna Schram, (650) 446-7888 xt 114
Director, Investor Relations
Source: CohBar, Inc.
Released October 13, 2016